Comparative Pharmacology
Head-to-head clinical analysis: TRI LO MILI versus TRI NORINYL 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO MILI versus TRI NORINYL 21 DAY.
TRI-LO-MILI vs TRI-NORINYL 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects, increases viscosity of cervical mucus, alters endometrial morphology, and inhibits ovulation.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
One tablet (35 mcg ethinyl estradiol, 0.5 mg norethindrone for 7 days, 1 mg norethindrone for 9 days, 0.5 mg norethindrone for 5 days) orally once daily for 21 days, then 7 days off. Start on first day of menstrual period or first Sunday after onset.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-23 hours. Steady-state reached within 5-7 days; clinical relevance for missed dose timing and resumption of ovulation.
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Renal: ~50-60% (as metabolites); Fecal: ~30-40% (via bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive